← Back to Search

Other

MC-1101 active for Age-Related Macular Degeneration (McCP2/3 Trial)

Phase 2 & 3
Waitlist Available
Led By Mitchell J Goff, MD
Research Sponsored by MacuCLEAR, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights

McCP2/3 Trial Summary

This is a Phase II/III,vehicle controlled, double masked, single center study. A single eye of 60 individuals with mild to moderate non-exudative Age-Related Macular Degeneration (AMD) will be randomly assigned to receive either topical 1% MC-1101 or a vehicle control over 2 years. The study design will assess the efficacy, safety, and tolerability of MC-1101 for these patients. An analysis of the primary and secondary endpoints will be conducted when all subjects have completed Baseline, 1, 3, 6, 12,18 and 24 months.

Eligible Conditions
  • Age-Related Macular Degeneration

McCP2/3 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Visual Function
Secondary outcome measures
Safety and tolerability (incidence and severity of adverse events, ocular irritability, ocular hyperemia)

McCP2/3 Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MC-1101 activeExperimental Treatment1 Intervention
Topical Drug 1% Ophthalmic Solution Topically, two times per day; morning and bedtime
Group II: MC-1101 Vehicle ControlPlacebo Group1 Intervention
Topical Drug: Ophthalmic Solution Topically, two times per day; morning and bedtime
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MC-1101
2009
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

MacuCLEAR, Inc.Lead Sponsor
3 Previous Clinical Trials
73 Total Patients Enrolled
Mitchell J Goff, MDPrincipal InvestigatorRocky Mountain Retina Consultants

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration
2014. "Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02127463.
All > Age Related Macular Degeneration > Macular Degeneration
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top